Mankind Pharma has entered into a partnership with Innovent Biologics for licensing and commercialising Sintilimab for cancer in India.

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...

CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Acute Coronary Syndrome.

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

PF-07976016 is under development for the treatment of obesity. It is administered as oral solution and oral suspension. The drug candidate acts by targeting gastric inhibitory peptide (GIPR).

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.